Dicerna Shows Interest in Rare Diseases, Highlights Lack of Exclusivity with Core Tech | GenomeWeb

In breaking out its pipeline in detail for the first time as it looks to go public, Dicerna Pharmaceuticals revealed that it is following along with others in the RNAi therapeutics field, namely Alnylam Pharmaceuticals, by expanding its focus to include rare, genetically defined diseases rather than indications currently addressed by other therapeutic modalities.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: Neanderthal-derived DNA linked to modern ailments, and more.

Japan needs to catch up on its gene-editing research efforts, the Japan News writes.

Hundreds of people have signed an online petition calling for zero tolerance to sexual harassment in the sciences.

Jeff Huber, former Google X senior vice president, joins Grail as its CEO.